Although in vivo studies in rat uterus have provided evidence for a crosstalk between RXFP1 and ERα and demonstrated ERα-mediated oestrogenic effects with relaxin treatment [24,25], a direct oestrogenic action of relaxin in breast cancer has not been described. This evidence concerns the gene ESR1 and breast carcinoma.